OmniAb (OABI) Investor And Anlayst Day 2026 summary

Business model and portfolio

• Technology licensing spans transgenic animal libraries, screening platforms and AI-enabled discovery, generating upfront fees, services, milestones, royalties, equity and asset-sale proceeds.

• Portfolio at June 30, 2026: 110 active partners, 425 active programs and 34 clinical programs or approved products; 8 of the 10 largest global pharma companies are partners.

• Contracted potential milestones exceed $3B, including ~$340M from clinical-stage programs; >98% of active programs have future economics, and the average portfolio royalty rate is ~3.4%.

• Partners have committed or spent >$2.4B advancing clinical-stage programs; programs span oncology, immunology and inflammation, metabolic and other areas.

• Strategy is to develop and license discovery tools rather than buy royalty rights; 350+ technology patents support the platforms, alongside partner drug patents.

Partnering, pipeline and royalty outlook

• Licensing options include standard technology access, service-led ion-channel screening, equity-linked entrepreneur enablement and advanced-asset deals; standard licenses combine fees, milestones and royalties, with flexible payment timing targeting risk-adjusted NPV neutrality.

• Newer chicken-based and novel-scaffold technologies drive many new partnerships; improved biotech funding is reflected in existing partners starting programs and inbound interest from new partners.

• The August Eli Lilly ion-channel deal carries substantial downstream economics; multi-year agreements can include larger license and service fees, milestones and royalties.

• Late-stage programs include Phase 3 IMVT-1402, precemtabart tocentecan and TEV-408; up to 19 partner clinical trials could reach primary completion in the remaining months of 2026 and in 2027, including potential pivotal readouts for IMVT-1402 and Ramantamig.

• Near-term drivers include late-stage milestones and a potential IMVT-1402 launch; longer-term launches and a larger xPloration install base are expected to broaden revenue, with multiple potential launches in the 2029–2034 outlook.

Discovery platforms and OmniTides

• Transgenic chicken platforms support conventional IgG, common-light-chain bispecific, single-domain and ultralong-CDR formats, including OmniChicken, OmniClic, OmnidAb and OmniUltra.

• OmnidAb pre-engineers human VHH frameworks for in vivo optimization; one partner received candidates in under seven months, selected a lead in December 2024 and began Phase 1 in Q4 2025, potentially saving 6–12 months of development time.

• OmniTides extends OmniUltra into peptide discovery with natural immune diversification, in vivo optimization and an integrated discovery-to-synthesis workflow, supported by qualified manufacturing partners and CROs.

• Peptides are positioned for standalone therapies, conjugates and other applications; market estimates are $117B in 2026 and $333B by the mid-2030s, with an 11% CAGR.